Bristol-Myers Squibb Company

NYSE:BMY Lagerbericht

Marktkapitalisierung: US$124.4b

Bristol-Myers Squibb Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Der Umsatz und der Gewinn von Bristol-Myers Squibb werden voraussichtlich um 6.6% bzw. 2.4% pro Jahr zurückgehen. Der Gewinn je Aktie wird voraussichtlich um 1% pro Jahr sinken. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 37.4% betragen.

Wichtige Informationen

-2.4%

Wachstumsrate der Gewinne

-1.03%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum14.9%
Wachstumsrate der Einnahmen-6.6%
Zukünftige Eigenkapitalrendite37.39%
Analystenabdeckung

Good

Zuletzt aktualisiert20 Jul 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Jul 03

Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes

Summary BMY’s growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1’26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow. I reiterate my Buy rating for patient, income-oriented investors, with the recommendation to accumulate at yields above 4.2% for an inflation beating income thesis. Read the full article on Seeking Alpha
Narrative-Update • Jun 16

BMY: Late Stage Pipeline Wins And Policy Risks Will Drive Re Rating

Analysts slightly revised their average price target for Bristol-Myers Squibb stock, reflecting updated views on a modestly softer revenue outlook, stable fair value near $75.00, and largely unchanged long term margin and P/E assumptions following recent commentary on Medicare negotiation risk. Analyst Commentary Bristol-Myers Squibb continues to attract mixed but constructive attention from Wall Street, with recent notes focusing on Medicare negotiation risk, price target fine-tuning, and how current valuation lines up with long term earnings power.
Analyseartikel • Jun 16

Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion

Bristol-Myers Squibb (BMY) stock is back in focus after the company expanded its kidney cancer trial through a clinical collaboration with Arcus Biosciences, adding new casdatifan arms to the ROSETTA RCC-208 study. See our latest analysis for Bristol-Myers Squibb. The kidney cancer trial expansion comes after a mixed period for Bristol-Myers Squibb, with the share price at $56.24, a year to date share price return of 5.2%, and a 1 year total shareholder return of 21.35%. This suggests...
Narrative-Update • Jun 02

BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating

Analysts have raised the average Bristol-Myers Squibb price target by a few dollars, citing a series of recent upward revisions into the $60 to $70 range. These revisions reflect ongoing debate around macro risks, healthcare sector positioning, and upcoming Milvexian Phase III data.
Narrative-Update • May 18

BMY: Pipeline Execution And Macro Shifts Will Shape Future Risk Balance

Analysts now see Bristol-Myers Squibb’s fair value edging down by $0.08 to $62.96, as they factor in slightly weaker revenue growth and profit margin assumptions alongside a higher future P/E, even as recent Street price target moves reflect mixed views on the stock’s pipeline and macro setup. Analyst Commentary Recent Street commentary on Bristol-Myers Squibb highlights a wide range of views on execution risk, pipeline delivery and how those factors may feed into valuation over the next few years.
Narrative-Update • May 03

BMY: Upcoming Late Stage Readouts Will Drive Potential Re Rating Opportunity

Analysts have made only a modest adjustment to their Bristol-Myers Squibb outlook, with small changes to revenue and profitability assumptions feeding into updated price targets that cluster in a wide range from about $60 to $75. This reflects differing views on the pipeline and upcoming Milvexian data as potential drivers for the story.
Narrative-Update • Apr 19

BMY: Pipeline Progress And Sector Shifts Will Shape Future Risk Balance

Analysts have raised the implied fair value for Bristol-Myers Squibb to $63.04 from $59.91, reflecting a series of recent price target increases based on slightly less severe revenue contraction expectations, a modest improvement in projected profit margins, and support from pipeline-related research updates across multiple firms. Analyst Commentary Recent research has focused on how Bristol-Myers Squibb balances patent expirations on key products with progress in its pipeline and late stage programs, and how that mix feeds into valuation, execution risk, and potential growth beyond current revenue headwinds.
Narrative-Update • Apr 04

BMY: 2026 Catalyst Calendar Will Likely Fail To Offset Patent Cliff

Analyst price targets for Bristol-Myers Squibb have moved higher into a broad $60 to $75 range, with analysts pointing to a rich 2026 catalyst calendar, emerging pipeline readouts such as milvexian Phase III data, and relatively lower exposure to AI disruption risks as key supports for the updated views. Analyst Commentary Recent research highlights a mix of optimism and caution around Bristol-Myers Squibb, with the Street focusing on a packed 2026 catalyst calendar, milvexian Phase III data, and a broad set of late stage assets.
Narrative-Update • Mar 21

BMY: 2026 Late Stage Pipeline Catalysts Will Likely Limit Further Upside

The analyst price target for Bristol Myers Squibb has moved higher, with the fair value estimate shifting from $40.67 to $45.67 as analysts point to a richer pipeline of late stage catalysts, a higher projected profit margin, and sector wide support from the appeal of healthcare during a choppy macro backdrop. Analyst Commentary Recent research coverage on Bristol Myers Squibb has tilted more constructive, with several firms lifting price targets into the US$60 to US$75 range and highlighting a dense calendar of late stage readouts through 2026.
Narrative-Update • Mar 06

BMY: 2026 Late-Stage Pipeline Readouts Will Shape Re-Rating Potential

Analysts have lifted their Bristol Myers Squibb fair value estimate from $68.00 to $75.00, citing higher Street price targets and an increased focus on pipeline catalysts such as the Phase III milvexian data and a dense slate of 2026 readouts. Analyst Commentary Recent Street research on Bristol Myers Squibb clusters around a more constructive view of the pipeline, especially the 2026 readout slate and the Phase III milvexian program, with several firms revisiting their valuation frameworks in light of these potential catalysts.
Narrative-Update • Feb 20

BMY: 2026 Pipeline Catalysts And Sector Recovery Will Shape Risk Balance

Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to about $60. This reflects how recent price target increases and generally constructive research commentary around the pipeline are starting to offset concerns about upcoming patent expirations.
Analyseartikel • Feb 18

We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit

Bristol-Myers Squibb Company ( NYSE:BMY ) announced a healthy earnings result recently, and the market rewarded it with...
Narrative-Update • Feb 06

BMY: 2026 Pipeline Readouts And Sector Recovery Will Guide Next Repricing

Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to US$58.13 from US$56.26. This reflects updated Street research in which analysts cite a richer mix of potential 2026 pipeline catalysts and a slightly higher assumed future P/E multiple, both of which support recent price target increases across several firms.
Narrative-Update • Jan 23

BMY: 2026 Pipeline Readouts Will Likely Cap Near Term Upside

Analysts have lifted their blended price target on Bristol Myers Squibb by roughly US$2 to reflect higher estimated fair value and profitability, citing a rich set of 2026 pipeline readouts and what they view as underappreciated upside in several late-stage assets. Analyst Commentary Recent Street research on Bristol Myers Squibb points to a mixed but generally constructive stance, with several firms lifting price targets into the US$53 to US$65 range and highlighting what they see as meaningful 2026 data catalysts across eight late stage assets.
Narrative-Update • Jan 08

BMY: Sector Tailwinds And Pipeline Milestones Will Shape Next Share Rerating

Analysts have nudged their price targets for Bristol Myers Squibb higher, with moves such as UBS shifting to a Buy rating with a US$65 target from US$46 and Citi lifting its target to US$53 from US$45. This reflects growing confidence tied to sector tailwinds, improving deal activity, and a refreshed view of the company’s valuation and earnings power.
Narrative-Update • Dec 25

BMY: Sector Perform View Will Limit Upside Despite Upcoming Earnings Focus

Analysts have nudged their fair value estimate for Bristol-Myers Squibb higher to about $38.41 from $35.86, reflecting a modestly richer future earnings multiple despite slightly weaker near term revenue growth and margin assumptions, and a new $45 price target under a Sector Perform view. Analyst Commentary Recent Street commentary frames Bristol-Myers Squibb as a lagging, but not broken, story within large cap biopharma.
Narrative-Update • Dec 11

BMY: Sector Outlook And Policy Shifts Will Shape Next Share Rerating

Analysts have nudged their price target for Bristol-Myers Squibb slightly higher to approximately $54 per share. This reflects a modestly richer future earnings multiple despite expectations for somewhat weaker revenue growth and profit margins, along with a more cautious Sector Perform stance from recent Street research.
Narrative-Update • Sep 04

Aging Demographics And Genomics Will Drive Healthcare Demand

Analysts maintained a cautious outlook on Bristol-Myers Squibb due to muted Cobenfy prescription trends and pipeline execution concerns, partially offset by optimism for upcoming Alzheimer’s data and future optionality, resulting in the consensus price target remaining steady at $53.00. Analyst Commentary Bearish analysts point to recent moderation in Cobenfy prescriptions for schizophrenia and maintain low growth expectations for this indication in the second half of 2025.

Gewinn- und Umsatzwachstumsprognosen

NYSE:BMY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202841,0328,88514,15014,49021
12/31/202746,39610,24414,64314,91524
12/31/202647,45810,54715,79314,50626
3/31/202648,4827,27511,90813,306N/A
12/31/202548,1947,05412,84514,156N/A
9/30/202548,0346,03915,30216,621N/A
6/30/202547,7045,04914,57815,901N/A
3/31/202547,6365,41913,08614,310N/A
12/31/202448,300-8,94813,94215,190N/A
9/30/202447,435-7,25813,80315,003N/A
6/30/202446,509-6,54112,94514,163N/A
3/31/202445,534-6,14812,50913,724N/A
12/31/202345,0068,02512,65113,860N/A
9/30/202344,9358,28511,46812,914N/A
6/30/202345,1877,96310,49911,850N/A
3/31/202345,8487,31110,86012,224N/A
12/31/202246,1596,32711,94813,066N/A
9/30/202246,7386,67712,94613,817N/A
6/30/202247,1446,61714,50215,396N/A
3/31/202246,9606,25115,34716,195N/A
12/31/202146,3856,99415,23416,207N/A
9/30/202145,468-5,40514,56915,505N/A
6/30/202144,384-5,07911,68712,506N/A
3/31/202142,810-6,21913,21513,939N/A
12/31/202042,518-9,01513,29914,052N/A
9/30/202039,395-4412,15712,878N/A
6/30/202034,862-56312,40913,167N/A
3/31/202031,0069549,93910,757N/A
12/31/201926,1453,439N/A8,210N/A
9/30/201924,1735,655N/A8,458N/A
6/30/201923,8576,203N/A7,181N/A
3/31/201923,2885,144N/A6,155N/A
12/31/201822,5614,920N/A7,066N/A
9/30/201822,0371,432N/A4,628N/A
6/30/201821,600376N/A5,062N/A
3/31/201821,040919N/A5,589N/A
12/31/201720,7761,007N/A5,275N/A
9/30/201720,5704,229N/A5,601N/A
6/30/201720,2384,586N/A5,292N/A
3/31/201719,9654,836N/A4,147N/A
12/31/201619,4274,457N/A3,058N/A
9/30/201618,4713,366N/A2,226N/A
6/30/201617,6182,870N/A1,346N/A
3/31/201616,9101,574N/A978N/A
12/31/201516,5601,565N/A2,105N/A
9/30/201516,5311,775N/A1,793N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BMYFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-2.4% pro Jahr).

Ertrag vs. Markt: BMYFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-2.4% pro Jahr).

Hohe Wachstumserträge: BMYFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: BMYDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-6.6% pro Jahr).

Hohe Wachstumseinnahmen: BMYDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-6.6% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BMYDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (37.4%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/07/22 21:34
Aktienkurs zum Tagesende2026/07/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Bristol-Myers Squibb Company wird von 45 Analysten beobachtet. 26 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
David ToungArgus Research Company
Emily FieldBarclays
Charles ButlerBarclays